in vitro News and Research

RSS

ETH Zurich, University of Zurich jointly open new translational research centre

ETH Zurich and the University of Zurich are taking their long-standing partnership to a new level with a new translational research centre. The two universities are founding the Wyss Translational Center Zurich (WTZ) with funds donated by Hansjörg Wyss to the ETH Zurich Foundation.

14 Dec 2014

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

With cancer rates rising worldwide, and Cancer Research UK predicting that the lifetime risk of cancer will reach 50% by 2027, the need for early diagnosis is overwhelming. Now, a British research group has published details of a simple empirical test to detect any early-stage cancer, relying on Andor's Komet software to automatically score the modified 3D 'Comet' assay results.

From Andor Technology Ltd. 11 Dec 2014

Scientists report new family of selective molecules to combat causal agent of malaria

Malaria is one of the most serious health problems worldwide, registering 200 million clinical cases and more than 600,000 attributable deaths per year, according to information from the World Health Organization in 2013. Given the emerging resistance to the standard treatment most widely used throughout the world, which is based on artemisinin and its analogs, there is a need for new antimalarial compounds.

11 Dec 2014

New study investigates Ebola protein

A new study by Robert Stahelin, an adjunct associate professor of chemistry and biochemistry at the University of Notre Dame and an associate professor at the Indiana University School of Medicine-South Bend, as well as a member of Notre Dame's Eck Institute for Global Health, investigates how the most abundant protein that composes the Ebola virus, VP 40, mediates replication of a new viral particle.

11 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

University of Illinois study could provide insight into protein-misfolding diseases

When a large protein unfolds in transit through a cell, it slows down and can get stuck in traffic. Using a specialized microscope -- a sort of cellular traffic camera -- University of Illinois chemists now can watch the way the unfolded protein diffuses.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.

From Quest Diagnostics 9 Dec 2014

MD Anderson study sheds light on miR569 gene

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

9 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

New technique measures antioxidant capacities of citrus juices

The antioxidant activity of citrus juices and other foods is undervalued. A new technique developed by researchers from the University of Granada for measuring this property generates values that are ten times higher than those indicated by current analysis methods. The results suggest that tables on the antioxidant capacities of food products that dieticians and health authorities use must be revised.

5 Dec 2014

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels.

4 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

Interventional radiology procedure can preserve fertility, save lives of women with placenta accreta

Researchers reported today on a procedure that can preserve fertility and potentially save the lives of women with a serious pregnancy complication called placenta accreta. Results of the new study presented at the annual meeting of the Radiological Society of North America showed that placement of balloons in the main artery of the mother's pelvis prior to a Caesarean section protects against hemorrhage and is safe for both mother and baby.

3 Dec 2014

Rhine-Waal students bag first place in research poster competition at European Detergents Conference

Rhine-Waal students Aleksandar Hizman, Sabine Vollmer, Chantal Baumann, Kim Krieger and Lars Frohn, undergraduates in the Quality, Environment, Safety and Hygiene programme of the Faculty of Life Sciences, won first place in a research poster competition at the 10th annual European Detergents Conference, held in conjunction with the SEPAWA Congress in Fulda, Germany.

3 Dec 2014

Maternal age and successful egg freezing with PGS: an interview with Dr. Santiago Munné

The leading cause of of pregnancy loss or infertility is chromosomal abnormality or imbalance, where extra genetic material is present or some is missing - what’s called aneuploidy. This imbalance leads to the inability to produce viable embryos or pregnancy.

2 Dec 2014

Faster and more accurate method for testing new cancer drugs

Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers.

2 Dec 2014

Cepheid gets FDA clearance to market Xpert Norovirus

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

in vitro News and Research

ETH Zurich, University of Zurich jointly open new translational research centre

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

Scientists report new family of selective molecules to combat causal agent of malaria

New study investigates Ebola protein

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

University of Illinois study could provide insight into protein-misfolding diseases

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

MD Anderson study sheds light on miR569 gene

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

New technique measures antioxidant capacities of citrus juices

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Interventional radiology procedure can preserve fertility, save lives of women with placenta accreta

Rhine-Waal students bag first place in research poster competition at European Detergents Conference

Maternal age and successful egg freezing with PGS: an interview with Dr. Santiago Munné

Faster and more accurate method for testing new cancer drugs

Cepheid gets FDA clearance to market Xpert Norovirus

iCo Therapeutics announces corporate update and Q3 2014 financial results

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News